{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:41:42Z","timestamp":1781739702278,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,4,22]],"date-time":"2012-04-22T00:00:00Z","timestamp":1335052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Infliximab and adalimumab are highly effective in <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>rohn's <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>isease (<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>). This is supported by clinical trials and open\u2010label studies using either infliximab or adalimumab, thus not allowing a proper comparison between these anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>s in <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the efficacy and safety of infliximab and adalimumab in active <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a longitudinal study, <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content> patients with indication for anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>s were treated with infliximab or adalimumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010three patients were treated with infliximab (<jats:italic>n\u00a0<\/jats:italic>=\u00a044) or adalimumab (<jats:italic>n\u00a0<\/jats:italic>=\u00a049). In the infliximab group, the induction was completed by 77.3% of patients, due to no response (<jats:italic>n\u00a0<\/jats:italic>=\u00a02), delayed hypersensitivity reactions (<jats:styled-content style=\"fixed-case\">DHR<\/jats:styled-content>) or infusion reactions (<jats:italic>n\u00a0<\/jats:italic>=\u00a08). Maintenance with infliximab was completed by 60% of patients, due to clinical worsening or loss of efficacy (<jats:italic>n\u00a0<\/jats:italic>=\u00a05), <jats:styled-content style=\"fixed-case\">DHR<\/jats:styled-content> or infusion reactions (<jats:italic>n\u00a0<\/jats:italic>=\u00a05). In the adalimumab group, all patients completed the induction, while maintenance was completed by 67% of patients, due to clinical worsening or loss of efficacy (<jats:italic>n\u00a0<\/jats:italic>=\u00a08), <jats:styled-content style=\"fixed-case\">DHR<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=\u00a01), other causes (<jats:italic>n\u00a0<\/jats:italic>=\u00a07). In both groups, the <jats:styled-content style=\"fixed-case\">CDAI<\/jats:styled-content> significantly reduced at baseline vs. each visit (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.04). The Kaplan\u2013Meier survival analysis performed to evaluate the risk of steroid\u2010free remission in patients treated with infliximab vs. adalimumab detected no differences (log\u2010rank test <jats:italic>P\u00a0<\/jats:italic>=\u00a00.4). Cox proportional\u2010hazards regression identified two predictors of steroid\u2010free remission using anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>s: no smokers [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a02.94 (1.52\u20135.70), <jats:italic>P\u00a0<\/jats:italic>=\u00a00.001] and non stricturing non penetrating behaviour [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\u00a0=\u00a03.116 (1.06\u20139.13), <jats:italic>P\u00a0<\/jats:italic>=\u00a00.03826].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Infliximab and adalimumab showed a similar efficacy. No smoking and non\u2010stricturing non\u2010penetrating behaviour were predictors of steroid\u2010free remission.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2012.05100.x","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T04:12:10Z","timestamp":1335154330000},"page":"1397-1407","source":"Crossref","is-referenced-by-count":59,"title":["Efficacy and safety of infliximab and adalimumab in <scp>C<\/scp>rohn's disease: a single centre study"],"prefix":"10.1111","volume":"35","author":[{"given":"F.","family":"Zorzi","sequence":"first","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zuzzi","sequence":"additional","affiliation":[{"name":"Centro Interdipartimentale di Biostatistica e Bioinformatica Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Onali","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Condino","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Petruzziello","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ascolani","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pallone","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Biancone","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Gastroenterologia Dipartimento di Medicina Interna Universit\u00e0 di Roma \u2018Tor Vergata\u2019  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101225"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.443"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90398-0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03339-X"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2005.08.011"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.002"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.01.035"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03232.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2009.12.003"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.07.010"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90697-1"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.006"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-10-200111200-00011"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)90905-0"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155812"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.004"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05786.x"},{"key":"e_1_2_6_30_1","first-page":"A2642","article-title":"Infliximab in Crohn's disease: first anniversary clinical experience","volume":"94","author":"Cohen RD","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03366.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21272"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.116467"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000228573"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05991.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.07.011"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2012.05100.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2012.05100.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:12:13Z","timestamp":1698757933000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2012.05100.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,22]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1111\/j.1365-2036.2012.05100.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05100.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,22]]}}}